MONTREAL and CHARLOTTE,
N.C., Sept. 5, 2023 /CNW/ -- Milestone
Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company
focused on the development and commercialization of innovative
cardiovascular medicines, today announced that members of its
management team will participate in a fireside chat at the H.C.
Wainwright 25th Annual Global Investment Conference on
Tuesday, September 12, 2023 at
9:00 a.m. ET.
A live webcast of the fireside chat can be accessed in the News
& Events section of Milestone's website
at www.milestonepharma.com. An archived replay of the fireside
chat will be available on the same website for approximately 90
days following the presentation.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a
biopharmaceutical company focused on the development and
commercialization of innovative cardiovascular medicines.
Milestone's lead product candidate etripamil recently completed its
Phase 3 clinical-stage program for the treatment of paroxysmal
supraventricular tachycardia (PSVT) and is in a Phase 2
proof-of-concept trial for the treatment of patients with atrial
fibrillation with rapid ventricular rate (AFib-RVR). Milestone
Pharmaceuticals operates in Canada
and the United States. For more
information, visit www.milestonepharma.com and follow Milestone on
Twitter at @MilestonePharma.
Contact
David Pitts
Argot Partners
212-600-1902
milestone@argotpartners.com
View original
content:https://www.prnewswire.com/news-releases/milestone-pharmaceuticals-to-present-at-the-hc-wainwright-25th-annual-global-investment-conference-301916144.html
SOURCE Milestone Pharmaceuticals, Inc.